title: Ketotifen fumarate and olopatadine hydrochloride in the treatment of allergic conjunctivitis: a real-world comparison of efficacy and ocular comfort.
abstract: This 3-week prospective, randomized, double-masked, parallel-group study compared ketotifen fumarate 0.025% ophthalmic solution and olopatadine hydrochloride 0.1% ophthalmic solution in 66 patients with seasonal allergic conjunctivitis. The drugs were instilled twice daily. Signs and symptoms were assessed on days 5 (visit 2) and 21 (visit 3). Other efficacy variables were the responder rate (patients with excellent or good global efficacy on days 5 and 21) and patient and investigator ratings of global efficacy. Comfort was evaluated immediately after instillation of the first drop and at each follow-up visit. The frequency of adverse events was the safety assessment. The responder rate was higher with ketotifen than with olopatadine on day 5 (72% vs 54% for patient assessment, 88% vs 55% for investigator assessment) and day 21 (91% vs 55%, 94% vs 42%). Global efficacy ratings were higher with ketotifen, and severity scores for hyperemia and itching were significantly lower. Both drugs elicited comparable comfort ratings. The most common adverse events were burning/stinging and headache.
authors.affiliation: Ganz Allergy and Asthma Center, Racine, Wisconsin 53406-4050, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Ganz
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Koll
authors.forename: Jean
authors.initials: J
authors.lastname: Gausche
authors.forename: Paul
authors.initials: P
authors.lastname: Detjen
authors.forename: Nicholas
authors.initials: N
authors.lastname: Orfan
mesh_terms: D000328:Adult; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D003228:Conjunctiva / Q000187:drug effects*; D003233:Conjunctivitis, Allergic / Q000188:drug therapy* / Q000503:physiopathology; D003990:Dibenzoxepins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007665:Ketotifen / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015146:Midwestern United States; D000069605:Olopatadine Hydrochloride; D009883:Ophthalmic Solutions; D010147:Pain Measurement / Q000523:psychology*; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018926:Anti-Allergic Agents; D003990:Dibenzoxepins; D009883:Ophthalmic Solutions; D000069605:Olopatadine Hydrochloride; D007665:Ketotifen